Artigo Acesso aberto Revisado por pares

Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study

2024; Multidisciplinary Digital Publishing Institute; Volume: 13; Issue: 14 Linguagem: Inglês

10.3390/jcm13143992

ISSN

2077-0383

Autores

Silviu-Horia Morariu, Ovidiu Simion Cotoi, Oana Mirela Tiucă, Adrian Băican, Laura Gheucă Solovăstru, H. Decean, Ilarie Brihan, Katalin Silaghi, Viorica Biro, Diana Șerban-Pescar, Ioana Măgureanu, Mircea Ambros, Roxana Ioana Ilcuș, L. Prodan, Andreea Beatrix Bălan, Mădălina Aurelia Husariu, Dumitrița Lenuța Guguluș, Radu Alexandru Stan, Vlad Mihai Voiculescu, Alin Codruț Nicolescu,

Tópico(s)

Inflammatory mediators and NSAID effects

Resumo

: Psoriasis is an immune-mediated chronic disorder associated with various comorbidities. Even though biologics and small-molecule inhibitors are the mainstay treatment for moderate-to-severe psoriasis, there is no current consensus regarding which agent should be used for a specific type of patient. This paper aims to test the reliability of blood-count-derived inflammatory markers in assessing treatment response to biologics and small-molecule inhibitors in psoriasis.

Referência(s)